Zingg J M, Shen J C, Yang A S, Rapoport H, Jones P A
Department of Biochemistry and Molecular Biology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles 90033, USA.
Nucleic Acids Res. 1996 Aug 15;24(16):3267-75. doi: 10.1093/nar/24.16.3267.
The target cytosines of (cytosine-5)-DNA methyltransferases in prokaryotic and eukaryotic DNA show increased rates of C-->T transition mutations compared to non-target cytosines. These mutations are induced either by the spontaneous deamination of 5-mC-->T generating inefficiently repaired G:T rather than G:U mismatches, or by the enzyme-induced C-->U deamination which occurs under conditions of reduced levels of S-adenosylmethionine (AdoMet) and S-adenosylhomocysteine (AdoHcy). We tested whether various inhibitors of (cytosine-5)-DNA methyltransferases analogous to AdoMet and AdoHcy would affect the rate of enzyme-induced deamination of the target cytosine by M.HpaII and M.SssI. Interestingly, we found two compounds, sinefungin and 5'-amino-5'-deoxyadenosine, that increased the rate of deamination 10(3)-fold in the presence and 10(4)-fold in the absence of AdoMet and AdoHcy. We have therefore identified the first mutagenic compounds specific for the target sites of (cytosine-5)-DNA methyltransferases. A number of analogs of AdoMet and AdoHcy have been considered as possible antiviral, anticancer, antifungal and antiparasitic agents. Our findings show that chemotherapeutic agents with affinities to the cofactor binding pocket of (cytosine-5)-DNA methyltransferase should be tested for their potential mutagenic effects.
与非靶向胞嘧啶相比,原核生物和真核生物DNA中(胞嘧啶-5)-DNA甲基转移酶的靶向胞嘧啶显示出更高的C→T转换突变率。这些突变要么是由5-甲基胞嘧啶自发脱氨生成修复效率低下的G:T错配而非G:U错配引起的,要么是由在S-腺苷甲硫氨酸(AdoMet)和S-腺苷高半胱氨酸(AdoHcy)水平降低的条件下发生的酶诱导的C→U脱氨引起的。我们测试了与AdoMet和AdoHcy类似的各种(胞嘧啶-5)-DNA甲基转移酶抑制剂是否会影响M.HpaII和M.SssI对靶向胞嘧啶的酶诱导脱氨速率。有趣的是,我们发现了两种化合物,西奈芬净和5'-氨基-5'-脱氧腺苷,它们在有AdoMet和AdoHcy存在时将脱氨速率提高了10³倍,在没有AdoMet和AdoHcy时提高了10⁴倍。因此,我们鉴定出了第一种对(胞嘧啶-5)-DNA甲基转移酶靶向位点具有特异性的诱变化合物。许多AdoMet和AdoHcy的类似物已被认为可能是抗病毒、抗癌、抗真菌和抗寄生虫药物。我们的研究结果表明,应对与(胞嘧啶-5)-DNA甲基转移酶辅因子结合口袋具有亲和力的化疗药物进行潜在诱变作用的测试。